{"result": {"id": "960587fc-e49c-4cbb-bcae-6d469f3526f9", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>CYP2C8<|>ORGANIZATION<|>CYP2C8 is an enzyme involved in the metabolism of drugs like repaglinide, and its inhibition can significantly slow down drug metabolism\")  \n##\n(\"entity\"<|>瑞格列奈 (REPAGLINIDE)<|>PERSON<|>Repaglinide is a drug whose metabolism is significantly slowed by CYP2C8 inhibitors, leading to increased blood concentration and risk of severe hypoglycemia\")  \n##\n(\"entity\"<|>吉非罗齐 (GEMFIBROZIL)<|>PERSON<|>Gemfibrozil is a drug that inhibits CYP2C8, increasing repaglinide's AUC and half-life, raising the risk of severe hypoglycemia\")  \n##\n(\"entity\"<|>卡格列净 (CANAGLIFLOZIN)<|>PERSON<|>Canagliflozin is a drug whose metabolism is affected by rifampin, leading to reduced efficacy and potential hyperglycemia\")  \n##\n(\"entity\"<|>利福平 (RIFAMPIN)<|>PERSON<|>Rifampin is a drug that induces UGT enzymes, accelerating the metabolism of canagliflozin and reducing its effectiveness\")  \n##\n(\"entity\"<|>地高辛 (DIGOXIN)<|>PERSON<|>Digoxin is a drug that shows no clinically relevant interaction when co-administered with canagliflozin\")  \n##\n(\"entity\"<|>UGT<|>ORGANIZATION<|>UGT (UDP-glucuronosyltransferase) is an enzyme family involved in drug metabolism, including the breakdown of canagliflozin\")  \n##\n(\"entity\"<|>CYP3A4<|>ORGANIZATION<|>CYP3A4 is an enzyme that metabolizes many drugs, and its induction can lead to reduced drug efficacy or increased blood pressure fluctuations\")  \n##\n(\"entity\"<|>氨氯地平 (AMLODIPINE)<|>PERSON<|>Amlodipine is a drug with moderate CYP3A4 inhibitory effects, requiring caution when co-administered with simvastatin\")  \n##\n(\"entity\"<|>辛伐他汀 (SIMVASTATIN)<|>PERSON<|>Simvastatin is a drug whose dosage must be limited when co-administered with amlodipine due to CYP3A4 inhibition\")  \n##\n(\"entity\"<|>ACEI<|>ORGANIZATION<|>ACE inhibitors are a class of drugs rarely metabolized by CYP450 enzymes but have pharmacodynamic interactions with other drugs\")  \n##\n(\"entity\"<|>ARB<|>ORGANIZATION<|>Angiotensin II receptor blockers are a class of drugs with minimal CYP450 metabolism but potential pharmacodynamic interactions\")  \n##\n(\"entity\"<|>沙库巴曲 (SACUBITRIL)<|>PERSON<|>Sacubitril is a drug that, when combined with ACE inhibitors, increases the risk of angioedema\")  \n##\n(\"entity\"<|>阿利吉仑 (ALISKIREN)<|>PERSON<|>Aliskiren is a drug that, when combined with ACE inhibitors or ARBs in diabetics, increases risks of hypotension, hyperkalemia, and renal impairment\")  \n##\n(\"relationship\"<|>瑞格列奈 (REPAGLINIDE)<|>吉非罗齐 (GEMFIBROZIL)<|>Gemfibrozil inhibits CYP2C8, significantly increasing repaglinide's blood concentration and risk of severe hypoglycemia<|>9\")  \n##\n(\"relationship\"<|>卡格列净 (CANAGLIFLOZIN)<|>利福平 (RIFAMPIN)<|>Rifampin induces UGT, accelerating canagliflozin's metabolism and reducing its efficacy<|>8\")  \n##\n(\"relationship\"<|>卡格列净 (CANAGLIFLOZIN)<|>地高辛 (DIGOXIN)<|>No clinically relevant interaction observed between canagliflozin and digoxin<|>2\")  \n##\n(\"relationship\"<|>氨氯地平 (AMLODIPINE)<|>辛伐他汀 (SIMVASTATIN)<|>Amlodipine inhibits CYP3A4, requiring simvastatin dosage limitation to avoid adverse effects<|>7\")  \n##\n(\"relationship\"<|>ACEI<|>沙库巴曲 (SACUBITRIL)<|>Combining ACE inhibitors with sacubitril increases the risk of angioedema<|>8\")  \n##\n(\"relationship\"<|>ACEI<|>阿利吉仑 (ALISKIREN)<|>Combining ACE inhibitors with aliskiren in diabetics increases risks of hypotension, hyperkalemia, and renal impairment<|>9\")  \n##\n(\"relationship\"<|>ARB<|>阿利吉仑 (ALISKIREN)<|>Combining ARBs with aliskiren in diabetics increases risks of hypotension, hyperkalemia, and renal impairment<|>9\")  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752166480, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 1116, "prompt_tokens": 2517, "total_tokens": 3633, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 725}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 基 β- 葡萄糖醛酸代谢物 是 CYP2C8 时间依赖性的强抑制剂，显 著减慢瑞格列奈的代谢\t谨慎合用\n瑞格列奈\t吉非罗齐\t严重低血糖\t合用吉非罗齐使瑞格列奈 AUC 增加 8.1 倍，t1/2 由 1.3 h 延长至 3.7 h，瑞格列奈血药浓度升高\t　吉非罗齐及其代谢物能显著抑制瑞格列 奈经 CYP2C8 的代谢\t避免合用\n卡格列净\t利福平\t高血糖\t和 t1/2 延长增加发生严重低血糖的风险\n合用多剂量的利福平使卡格列净的 Cmax  降低 28%，AUC 减少 51%\t　推测利福平通过诱导 UGT 而加快卡格列 净的代谢\t谨慎合用\n卡格列净\t地高辛\t-\t合用卡格列净使地高辛的 Cmax 升高 36%，AUC 增加 20%，药物合用未发现与临床相关的安全 性事件\t无相互作用\t可以合用\n　　注：Cmax= 血药峰浓度，AUC= 生物利用度，tmax= 达峰时间，M- Ⅲ = 代谢产物Ⅲ,M- Ⅳ = 代谢产物Ⅳ,P-gp=P- 糖蛋白，UGT= 二磷酸尿 苷葡糖醛酸转移酶；- 为无此项\n\n\n　能导致严重低血压；CYP3A4 强诱导剂（如利福平、卡 马西平、苯巴比妥、苯妥英等）能加快这类药物的代谢， 会造成血压升高或者血压剧烈波动，临床应该避免或谨 慎合用。氨氯地平也具有 CYP3A4 中等抑制作用，与辛 伐他汀合用时，辛伐他汀日剂量不能超过 20 mg。\n4.2.2    ACEI 和 血 管紧 张 素 Ⅱ 受体 拮 抗 剂（ARB ）\nACEI 类药物包括卡托普利、贝那普利、福辛普利等， 这类药物在体内很少经过CYP450 酶代谢，较少发生药 动学的相互作用。但是 ACEI 与某些药物存在药效学的 相互作用：与保钾利尿药合用可导致高钾血症；与脑啡 肽酶抑制剂沙库巴曲合用增加血管神经性水肿风险；糖 尿病患者合用 ACEI 和阿利吉仑，双重阻断肾素 - 血管 紧张素 - 醛固酮（RASS ）系统， 能加重低血压、高血 钾和肾功能恶化的风险，应该避免合用。与非甾体类抗 炎药（NSAID ）合用因水钠潴留而减弱降压效果，增加 肾损伤风险。\n　　ARB 类药物包括厄贝沙坦、缬沙坦、 氯沙坦、替 米沙坦等，绝大多数在体内也不经过CYP450 酶代谢， 药动学相互作用较少见。ARB 与保钾利尿药合用可导 致血钾升高；糖尿病患者合用 ARB 和阿\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_db5176f92587860c7b47c1b442230ec3c64b65833a32d78c59b8af74c20120ce_v2"}